The curative nature of cell and gene therapies has the potential to transform our entire approach to healthcare. Approvals have so far been in niche indications but the successful application of similar technologies in broader indications is expected to follow.
As the list of approvals grows, so too does the pressure on payers. The record-breaking price tags for these innovative therapies reflect the savings in medical costs over time, but the sizable upfront costs could create significant challenges for the reimbursement system.
The UK’s Office of Health Economics (OHE) has conducted extensive research into tackling the unique challenges that cell and gene therapies create for industry, regulators, and payors. This event provided an opportunity to hear from our experts on:
- Innovative approaches to reimbursement
- Demonstrating the value of cell and gene therapies
- Addressing uncertainty whilst providing patient access
